Background: Evidence on the efficacy of Mepolizumab (MEPO) in Eosinophilic Granulomatosis with Polyangiitis (EGPA) is scarce [1]. Objectives: To assess the efficacy and safety of MEPO in real-life clinical practice. Methods: We retrospectively included patients diagnosed with EGPA and treated with MEPO (100 or 300 mg/month). MEPO efficacy was evaluated in the first 12 months in terms of systemic disease and asthma control. The occurrence of any adverse event (AE) was recorded. Results: 142 patients were included (38% males; median age 46.4 (IQR 36.7-54.4); 110 and 32 on MEPO 100 and 300 mg/month, respectively). General, ear-nose-throat, pulmonary, and neurological symptoms significantly decreased during treatment (table 1). MEPO accounted for a significant reduction in the BVAS (figure 1) and for a steroid sparing effect (figure 2). The proportion of patients with asthma attacks decreased by 90% at 12 months compared to t0, and asthma-related emergency accesses dropped from 17.4% to 2.3%. Overall, 21.1% of patients had a non-serious AE. Conclusion: MEPO effectively controlled systemic and respiratory EGPA symptoms in a large European cohort, with no major safety concerns.
OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS / Bettiol, A.; Urban, M. L.; Alberici, F.; Agostini, C.; Baldini, C.; Bozzolo, E.; Cameli, P.; Crimi, N.; Del Giacco, S.; Egan, A.; Espigol-Frigole, G.; Felicetti, M.; Folci, M.; Fraticelli, P.; Govoni, M.; Kernder, A.; Lombardi, C.; Lopalco, G.; Lunardi, C.; Mohammad, A. J.; Moosig, F.; Negrini, S.; Neumann, T.; Novikov, P.; Paolazzi, G.; Parronchi, P.; Quartuccio, L.; Racanelli, V.; Salvarani, C.; Samson, M.; Schroeder, J.; Sciascia, S.; Sinico, R. A.; Terrier, B.; Toniati, P.; Prisco, D.; Vaglio, A.; Emmi, G.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - ELETTRONICO. - 79:(2020), pp. 94-95. [10.1136/annrheumdis-2020-eular.5544]
OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS
Bettiol, A.;Urban, M. L.;Baldini, C.;Cameli, P.;Lunardi, C.;Parronchi, P.;Prisco, D.;Vaglio, A.;Emmi, G.
2020
Abstract
Background: Evidence on the efficacy of Mepolizumab (MEPO) in Eosinophilic Granulomatosis with Polyangiitis (EGPA) is scarce [1]. Objectives: To assess the efficacy and safety of MEPO in real-life clinical practice. Methods: We retrospectively included patients diagnosed with EGPA and treated with MEPO (100 or 300 mg/month). MEPO efficacy was evaluated in the first 12 months in terms of systemic disease and asthma control. The occurrence of any adverse event (AE) was recorded. Results: 142 patients were included (38% males; median age 46.4 (IQR 36.7-54.4); 110 and 32 on MEPO 100 and 300 mg/month, respectively). General, ear-nose-throat, pulmonary, and neurological symptoms significantly decreased during treatment (table 1). MEPO accounted for a significant reduction in the BVAS (figure 1) and for a steroid sparing effect (figure 2). The proportion of patients with asthma attacks decreased by 90% at 12 months compared to t0, and asthma-related emergency accesses dropped from 17.4% to 2.3%. Overall, 21.1% of patients had a non-serious AE. Conclusion: MEPO effectively controlled systemic and respiratory EGPA symptoms in a large European cohort, with no major safety concerns.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
